Aggregation of a monoclonal antibody induced by adsorption to stainless steel

Biotechnology and Bioengineering

Volumn 105, Issue 1, 2010, Pages 121-129

  Bee, Jared S ^a   Davis, Michele ^a   Freund, Erwin ^b   Carpenter, John F ^c   Randolph, Theodore W ^a  

^a UCB 450   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Adsorption; Kinetics; Mechanism; Monoclonal antibody; Protein aggregation; Stainless steel

Indexed keywords

ADSORBED LAYERS; ADSORPTION KINETICS; ADSORPTION LAYER; AGGREGATION PROCESS; BIOPHARMACEUTICAL PRODUCTS; BULK PHASE; CARBONYL GROUPS; INITIAL RATE; MASS SPECTRA; MICRO-PARTICLES; MONOCLONAL ANTIBODIES (MAB); POLYSORBATE 20; PROTEIN AGGREGATION; PROTEIN OXIDATION; RATE-LIMITING STEPS; SECOND ORDERS; STAINLESS STEEL SURFACE; STEEL SURFACE; SURFACE AGGREGATION; THERAPEUTIC PROTEIN; ZERO ORDER;

ADSORPTION; AGGLOMERATION; CORROSION RESISTANT ALLOYS; MARTENSITIC STAINLESS STEEL; MASS SPECTROMETRY; MONOCLONAL ANTIBODIES; PROTEINS; STEEL CORROSION; SURFACE PLASMON RESONANCE;

STAINLESS STEEL;

CARBONYL DERIVATIVE; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; POLYSORBATE 20; STAINLESS STEEL;

ADSORPTION; ARTICLE; GEL PERMEATION CHROMATOGRAPHY; KINETICS; LIGHT SCATTERING; MASS SPECTROMETRY; OXIDATION; PROTEIN AGGREGATION; PROTEIN CARBONYLATION; SURFACE PROPERTY;

ADSORPTION; ANTIBODIES, MONOCLONAL; HUMANS; MASS SPECTROMETRY; STAINLESS STEEL; SURFACE PROPERTIES;

EID: 73949093277     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22525     Document Type: Article

References (23)

1. Alford JR, Kendrick BS, Carpenter JF, Randolph TW. 2008. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. J Pharm Sci 97(8):3005-3021.
2. Bee JS. 2009. Effect of interfaces and shear on therapeutic protein stability. PhD Thesis, University of Colorado, www.proquest.com.
3. Bee JS, Chiu D, Sawicki S, Stevenson JL, Chatterjee K, Freund E, Carpenter JF, Randolph TW. 2009. Monoclonal antibody interactions with micro-and nanoparticles: Adsorption, aggregation, and accelerated stress studies. J Pharm Sci 98(9):3218-3238.
4. Biddlecombe JG, Craig AV, Zhang H, Uddin S, Mulot S, Fish BC, Bracewell DG. 2007. Determining antibody stability: Creation of solid-liquid interfacial effects within a high shear environment. Biotechnol Prog 23(5):1218-1222.
5. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in non-native protein aggregation. Pharm Res 20(9):1325-1336.
6. Duenas ET, Keck R, De Vos A, Jones AJS, Cleland JL. 2001. Comparison between light induced and chemically induced oxidation of rhVEGF. Pharm Res 18(10):1455-1460.
7. Fogler HS. 2006. Elements of chemical reaction engineering. Upper Saddle River, NJ: Pearson Education, Inc.
8. Griffiths SW, Cooney CL. 2002. Relationship between protein structure and methionine oxidation in recombinant human alpha 1-antitrypsin. Biochemistry 41(20):6245-6252.
9. Lam XM, Yang JY, Cleland JL. 1997. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 86(11):1250-1255.
10. Liu JL, Lu KV, Eris T, Katta V, Westcott KR, Narhi LO, Lu HS. 1998. In vitro methionine oxidation of recombinant human leptin. Pharm Res 15(4): 632-640.
11. Liu HC, Gaza-Bulseco G, Xiang T, Chumsae C. 2008. Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody. Mol Immunol 45(3):701-708.
12. Randolph TW, Carpenter JF. 2007. Engineering challenges of protein formulations. AIChE J 53(8):1902-1907.
13. Reubsaet JLE, Beijnen JH, Bult A, Hop E, Scholten SD, Teeuwsen J, Underberg WJM. 1998. Oxidation of recombinant methionyl human granulocyte colony stimulating factor. J Pharm Biomed Anal 17(2): 283-289.
14. Roberts CJ. 2007. Non-native protein aggregation kinetics. Biotechnol Bioeng 98(5):927-938.
15. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8(3):E501-E507.
16. Schellekens H. 2002. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24(11):1720-1740.
17. Shacter E. 2000. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 32(3-4):307-326.
18. Soenderkaer S, Carpenter JF, van de Weert M, Hansen LL, Flink J, Frokjaer S. 2004. Effects of sucrose on rFVIIa aggregation and methionine oxidation. Eur J Pharm Sci 21(5):597-606.
19. Stadtman ER, Levine RL. 2003. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 25(3-4):207-218.
20. Thirumangalathu R, Krishnan S, Bondarenko P, Speed-Ricci M, Randolph TW, Carpenter JF, Brems DN. 2007. Oxidation of methionine residues in recombinant human interleukin-1 receptor antagonist: Implications of conformational stability on protein oxidation kinetics. Biochemistry 46(21):6213-6224.
21. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C, Carpenter JF. 2009. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98(1):94-104.
22. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96(1):1-26.
23. Weiss WF, Young TM, Roberts CJ. 2009. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci 98(4):1246-1277.